Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Mereo Makes Senior Appointments

This article was originally published in Scrip

Executive Summary

Recently-formed biopharmaceutical company Mereo BioPharma Group Ltd. has appointed new members to its senior management and board. Paul Blackburn has been appointed non-executive board director and chair of the audit and risk committee; he joins Mereo from GlaxoSmithKline (GSK), where he was finance controller for almost 40 years. Anthony Hall has been appointed head of orphan diseases and previously was group medical director in the neuromuscular disease area at BioMarin. Jacqueline Parkin has been appointed Mereo's head of respiratory and endocrinology and joins the company from GSK where she held various senior clinical development roles for the past 13 years. Fiona Bor has been appointed head of intellectual property for Mereo and was previously vice president and global head of IP at Mylan Pharmaceuticals. Mereo has also appointed Ian Hodgson head of clinical operations; prior to this he was associate director, clinical operations and EMEA regional oncology lead at Takeda Oncology Company. In addition to these appointments, Stewart Jones has been appointed head of CMC, Craig Manchip head of QA and Julian Lord financial controller.

You may also be interested in...

Text Mining And Machine Reading: The Answer To Pharma's R&D Data Mountain?

How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.

Adherence Issues Add Weight To Digital Trials Push

Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.

Appointments: Five Prime, Depomed, Gilead, Arix Bioscience and Corbus

This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts